# Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.

> **NCT05858229** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sherrif Ibrahim** · enrollment: 12 (estimated)

## Conditions studied

- Squamous Cell Carcinoma
- RP1

## Interventions

- **DRUG:** RP1

## Key facts

- **NCT ID:** NCT05858229
- **Lead sponsor:** Sherrif Ibrahim
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-16
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858229, "Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05858229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*